bioMérieux S.A. (EPA:BIM)
74.35
+1.10 (1.50%)
May 29, 2026, 5:35 PM CET
bioMérieux Employees
As of December 31, 2025, bioMérieux had 15,226 total employees, including 14,562 full-time and 664 part-time employees. The number of employees increased by 472 or 3.20% compared to the previous year.
Employees
15,226
Change (1Y)
472
Growth (1Y)
3.20%
Revenue / Employee
€273,251
Profits / Employee
€26,689
Market Cap
8.77B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 15,226 | 472 | 3.20% | 14,562 | 664 |
| Dec 31, 2024 | 14,754 | 772 | 5.52% | 14,147 | 607 |
| Dec 31, 2023 | 13,982 | 847 | 6.45% | 13,409 | 573 |
| Dec 31, 2022 | 13,135 | 756 | 6.11% | 12,557 | 578 |
| Dec 31, 2021 | 12,379 | -245 | -1.94% | 12,084 | 295 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| EssilorLuxottica Société anonyme | 155,975 |
| emeis Société anonyme | 84,586 |
| Sanofi | 74,846 |
| Clariane SE | 70,685 |
| Eurofins Scientific SE | 65,694 |
| Ramsay Générale de Santé | 40,000 |
| Sartorius Stedim Biotech | 10,456 |
| Virbac | 6,442 |
bioMérieux News
- 3 days ago - bioMérieux Slides: FY 2026 - Filings
- 5 weeks ago - bioMérieux Earnings Call Transcript: Q1 2026 - Transcripts
- 5 weeks ago - bioMérieux Earnings release: Q1 2026 - Filings
- 3 months ago - bioMérieux Earnings Call Transcript: H2 2025 - Transcripts
- 3 months ago - bioMérieux Earnings release: H2 2025 - Filings
- 3 months ago - bioMérieux Slides: H2 2025 - Filings
- 3 months ago - bioMérieux Annual report: H2 2025 - Filings
- 7 months ago - bioMérieux Earnings Call Transcript: Q3 2025 - Transcripts